MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women

Journal of the National Cancer Institute

Volumn 106, Issue 9, 2014, Pages

  Tian, Qifang ^a   Li, Yang ^a   Wang, Fenfen ^a   Li, Ying ^a   Xu, Junfen ^a   Shen, Yuanming ^a   Ye, Feng ^a   Wang, Xinyu ^a   Cheng, Xiaodong ^a   Chen, Yaxia ^a   Wan, Xiaoyun ^a   Lu, Weiguo ^a   Xie, Xing ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 218; MICRORNA 34A; MICRORNA 375; MICRORNA 424; MICRORNA 92A; MICRORNA 93; TUMOR MARKER; UNCLASSIFIED DRUG; MIRN218 MICRORNA, HUMAN; MIRN34 MICRORNA, HUMAN; MIRN375 MICRORNA, HUMAN; MIRN424 MICRORNA, HUMAN; MIRN92 MICRORNA, HUMAN; MIRN93 MICRORNA, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CANCER SCREENING; COLPOSCOPY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC TEST ACCURACY STUDY; EMERGENCY HEALTH SERVICE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS; YOUDEN INDEX; ALPHAPAPILLOMAVIRUS; GENETICS; ISOLATION AND PURIFICATION; UTERINE CERVIX; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ADULT; ALPHAPAPILLOMAVIRUS; CERVIX UTERI; FEMALE; HUMANS; MICRORNAS; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TRIAGE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84929462778     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju241     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Arbyn M, Castellsagué X, De Sanjosé S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675-2686.
3. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907.
4. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16):1589-1597.
5. Whitlock E P, Vesco KK, Eder M, et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U. S. Preventive Services Task Force. Ann Intern Med. 2011;155(10):687-97, W214-W215.
6. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10(7):672-682.
7. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579-1588.
8. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249-257.
9. Franceschi S, Denny L, Irwin KL, et al. EUROGIN 2010 roadmap on cervical cancer prevention. Int J Cancer. 2011;128(12):2765-2774.
10. De Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453-459.
11. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11(9):597-610.
12. Pencheva N, Tavazoie S F. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol. 2013;15(6):546-554.
13. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513-10518.
14. Puerta-Gil P, Garcia-Baquero R, Jia AY, et al. miR-143, miR-222, and miR-452 Are Useful as Tumor Stratification and Noninvasive Diagnostic Biomarkers for Bladder Cancer. Am J Pathol. 2012;180(5):1808-1815.
15. Xie ZJ, Chen G, Zhang XC, et al. Salivary MicroRNAs as Promising Biomarkers for Detection of Esophageal Cancer. Plos One. 2013;8 (4).
16. Cui L, Zhang XJ, Ye GL, et al. Gastric Juice MicroRNAs as Potential Biomarkers for the Screening of Gastric Cancer. Cancer. 2013;119(9):1618-1626.
17. Li Y, Wang FF, Xu JF, et al. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. J Pathol. 2011;224(4):484-495.
18. Li B, Hu Y, Ye F, et al. Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection. Int J Gynecol Cancer. 2010;20(4):597-604.
19. Wang FF, Li Y, Zhou JS, et al. miR-375 Is Down-Regulated in Squamous Cervical Cancer and Inhibits Cell Migration and Invasion via Targeting Transcription Factor SP1. Am J Pathol. 2011;179(5):2580-2588.
20. Xu J, Li Y, Wang F, et al. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene. 2013;32(8):976-987.
21. Martinez I, Gardiner AS, Board KF, et al. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene. 2008;27(18):2575-2582.
22. Wang X, Meyers C, Guo M, et al. Upregulation of p18Ink4c expression by oncogenic HPV E6 via p53-miR-34a pathway. Int J Cancer. 2011;129(6):1362-1372.
23. Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197(4):346-355.
24. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114-2119.
25. Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. Lyon, France: IARC Press; 2003.
26. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-35.
27. Schisterman E F, Perkins NJ, Liu A, et al. Optimal cut-point and its corresponding youden index to discriminate individuals using pooled blood samples. Epidemiology. 2005;16(1):73-81.
28. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78-88.
29. Condel JL, Mahood LK, Grzybicki DM, et al. Papanicolaou tests diagnosed as atypical by a cytotechnologist and downgraded to benign by a pathologist - A measure of laboratory quality. Am J Clin Pathol. 2002;117(4):534-540.
30. Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of Liquid-Based Cytology With Conventional Cytology for Detection of Cervical Cancer Precursors: A Randomized Controlled Trial. JAMA. 2009;302(16):1757-1764.
31. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical cancer screening. N Engl J Med. 2003;348(6):489-490.
32. Zappacosta R, Caraceni D, Ciccocioppo L, et al. Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme. Gynecol Oncol. 2013;128(3):427-432.
33. Brosh R, Shalgi R, Liran A, et al. p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol. 2008;4:229.
34. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447(7148):1130-1134.